Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Drew Dula

Neurology Dayton, OH Doctor of Osteopathy

NPI 1386050821 CMS profile 1391533

1975 Miamisburg Centerville Rd, Dayton, OH 45459

Open in the dashboard

General payments

$13,291

701 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Drew Dula of Dayton, OH is reported in the CMS Open Payments database as having received $13,291 across 701 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,767 83
2024 General $1,835 74
2023 General $1,484 71
2022 General $2,136 107
2021 General $2,228 142
2020 General $1,255 82
2019 General $2,586 142

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Drew Dula
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Drew Dula were reported at $1,767. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Drew Dula Neurology median Middle half National median
2019 $2,586 $474 $118–$2,177 $163
2020 $1,255 $367 $82–$2,309 $114
2021 $2,228 $438 $104–$2,547 $132
2022 $2,136 $442 $103–$2,388 $149
2023 $1,484 $464 $119–$2,312 $160
2024 $1,835 $468 $119–$2,323 $164
2025 $1,767 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,183 94 payments
  2. Teva Pharmaceuticals USA, Inc. $854 57 payments
  3. UCB, Inc. $758 29 payments
  4. Novartis Pharmaceuticals Corporation $652 41 payments
  5. Alexion Pharmaceuticals, Inc. $647 30 payments
  6. Biogen, Inc. $612 34 payments
  7. Lilly USA, LLC $562 35 payments
  8. Neurocrine Biosciences, Inc. $559 41 payments
  9. Biohaven Pharmaceuticals, Inc. $464 25 payments
  10. Supernus Pharmaceuticals, Inc. $452 27 payments
  11. Other $5,548 288 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,183 696 payments
  2. Education $89 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19 3 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,105 49 payments
  2. QULIPTA $1,099 41 payments
  3. NURTEC ODT $633 35 payments
  4. AIMOVIG $546 26 payments
  5. INGREZZA $529 39 payments
  6. AJOVY $447 33 payments
  7. TROKENDI XR $425 25 payments
  8. Briviact $392 19 payments
  9. APTIOM $297 22 payments
  10. KESIMPTA $282 13 payments
  11. Other $7,714 430 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,145

Median for Neurology: 833

Drug cost

$106,283

Median for Neurology: $202,670

Branded share of claims

15.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Qulipta Atogepant Brand 27 $29,859
Ubrelvy Ubrogepant Brand 18 $21,140
Ajovy Autoinjector Fremanezumab-Vfrm Brand 14 $17,095
Nurtec Odt Rimegepant Sulfate Brand 16 $15,957
Levetiracetam Generic 96 $2,686
Entacapone Generic 14 $2,188
Teriflunomide Generic 11 $2,011
Memantine Hcl Generic 126 $1,999
Carbidopa-Levodopa Carbidopa/Levodopa Brand 75 $1,976
Pregabalin Generic 24 $1,601

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$307,154

Of which drugs: $262,328

Medicare patients

302

Average age 72

Services billed

7,126

164 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Depression 41%
Diabetes 37%
Ischemic heart disease 33%
Chronic kidney disease 28%
COPD 28%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$243 18 —
INGREZZA
$192 — —
Zilbrysq
$176 — —
ULTOMIRIS
$169 — —
Leqembi
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

701 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record